27.18

1.75% -0.485

After Hours: 27.18

Maze Therapeutics Inc (MAZE)

Overview News Price History Discussions Forecast

Maze Therapeutics Inc stock is traded at $27.18, with a volume of 230.65K. It is down -1.75% in the last 24 hours and down -9.04% over the past month. Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Previous Close:

$27.66

Open:

$27.47

24h Volume:

230.65K

Relative Volume:

0.41

Market Cap:

$1.51B

Revenue:

$2.50M

Net Income/Loss:

$-131.12M

P/E Ratio:

-9.56

EPS:

-2.8431

Net Cash Flow:

$-112.73M

1W Performance:

-5.13%

1M Performance:

-9.04%

6M Performance:

-40.93%

1Y Performance:

+103.60%

1-Day Range:

$26.85

$27.61

1-Week Range:

$26.42

$28.92

52-Week Range:

$12.81

$53.65

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name

Maze Therapeutics Inc

Sector

Healthcare (1080)

Industry

Biotechnology (604)

Phone

(650) 850-5070

Address

171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO

Employee

141

Twitter

Next Earnings Date

2026-08-11

Latest SEC Filings

MAZE's Discussions on Twitter

Compare MAZE vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MAZE Maze Therapeutics Inc	27.18	1.53B	2.50M	-131.12M	-112.73M	-2.8431
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Mar-10-26	Initiated	Mizuho	Outperform
Dec-04-25	Initiated	Wells Fargo	Overweight
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy
Jul-23-25	Initiated	H.C. Wainwright	Buy
Jul-08-25	Initiated	Wedbush	Outperform

View All

Maze Therapeutics Inc Stock (MAZE) Latest News

Aug 15, 2026

128,006 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Walleye Capital LLC - marketbeat.com

Aug 15, 2026

Maze Therapeutics (NASDAQ:MAZE) Lowered to Sell Rating by Wall Street Zen - marketbeat.com

Aug 15, 2026

Maze Therapeutics president sells $445,620 in company stock By Investing.com - Investing.com South Africa

Aug 15, 2026

Maze Therapeutics president sells $445,620 in company stock - Investing.com

Aug 15, 2026

Aug 14, 2026

Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CMO Sells $445,680.62 in Stock - marketbeat.com

Aug 14, 2026

Maze Therapeutics (MAZE) CMO exercises 16,142 options and sells shares under 10b5-1 plan - Stock Titan

Aug 14, 2026

Truist Financial Maintains Maze Therapeutics(MAZE.US) With Buy Rating, Announces Target Price $64 - moomoo.com

Aug 14, 2026

HC Wainwright Has Positive Estimate for MAZE Q3 Earnings - marketbeat.com

Aug 14, 2026

Aug 13, 2026

Maze Therapeutics adds two directors to board By Investing.com - Investing.com Australia

Aug 13, 2026

Maze Therapeutics adds two directors to board - Investing.com

Aug 13, 2026

Maze Therapeutics Announces Appointments to Its Board of Directors - The Manila Times

Aug 13, 2026

Maze Therapeutics Appoints Paula Johnson and Sophie Kornowski to Board of Directors - Quiver Quantitative

Aug 13, 2026

Maze Therapeutics, Inc. Common Stock (NASDAQ: MAZE) Stock Price, News & Analysis - kalkine.ca

Aug 13, 2026

Aug 12, 2026

Maze Therapeutics (NASDAQ:MAZE) Earns "Buy" Rating from BTIG Research - marketbeat.com

Aug 12, 2026

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - marketbeat.com

Aug 12, 2026

MAZE SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus

Aug 12, 2026

Aug 11, 2026

Maze Therapeutics (MAZE) reports $68.9M loss but ends Q2 with $494.9M in cash - Stock Titan

Aug 11, 2026

Maze Therapeutics (NASDAQ:MAZE) Announces Earnings Results - marketbeat.com

Aug 11, 2026

Earnings Flash (MAZE) Maze Therapeutics Posts Q2 Loss $0.76 per Share, vs. FactSet Est of $0.72 Loss - marketscreener.com

Aug 11, 2026

Maze Therapeutics Reports Q2 Net Loss Of $44.7 Million - Quiver Quantitative

Aug 11, 2026

Maze Therapeutics Q2 net loss widens, misses estimates on higher R&D expenses - TradingView

Aug 11, 2026

Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - The Manila Times

Aug 11, 2026

Press Release: Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - moomoo.com

Aug 11, 2026

Jason Coloma: The FTC Killed Our Sanofi Deal. Six Months Later, We Had a Better One. - finance.biggo.com

Aug 11, 2026

Maze Therapeutics (MAZE) Earnings Date and Reports 2026 - marketbeat.com

Aug 11, 2026

Aug 10, 2026

Maze Therapeutics (NASDAQ:MAZE) Trading Down 6.8%Should You Sell? - marketbeat.com

Aug 10, 2026